DSGN
Design Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -14.3% ·
share flow -3.7% ·
net new positions -16.7%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 61 | +2 | 14.66M | $212.03M | +5 | −3 |
| Q1 2026 | 61 | +2 | 13.39M | $142.37M | +4 | −2 |
| Q4 2025 | 59 | +1 | 16.55M | $155.25M | +1 | — |
| Q3 2025 | 16 | +1 | 10.74M | $80.90M | +1 | — |
| Q2 2025 | 12 | -2 | 9.77M | $32.93M | — | −2 |
| Q1 2025 | 11 | +2 | 5.33M | $20.59M | +2 | — |
| Q4 2024 | 9 | -2 | 5.31M | $32.78M | — | −2 |
| Q3 2024 | 10 | -1 | 4.34M | $23.36M | — | −1 |
| Q2 2024 | 11 | — | 4.24M | $14.20M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 2.40M | — | $8.07M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 2.40M | — | $8.07M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | BlackRock ✦ (passive) | 2.40M | — | $8.07M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | BlackRock ✦ (passive) | 2.40M | — | $8.07M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | BlackRock ✦ (passive) | 2.40M | — | $8.07M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | BlackRock ✦ (passive) | 2.40M | — | $8.07M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | BlackRock ✦ (passive) | 2.40M | — | $8.07M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | BlackRock ✦ (passive) | 2.40M | — | $8.07M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (passive) | 2.40M | — | $8.07M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 1.81M | -0.6% | $6.09M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 11 | The Vanguard Group ✦ (passive) | 1.47M | — | $4.96M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | The Vanguard Group ✦ (passive) | 1.47M | — | $4.96M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | The Vanguard Group ✦ (passive) | 1.47M | — | $4.96M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Fidelity (FMR) ✦ | 951.20K | — | $3.21M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 840.79K | -12.7% | $2.83M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Geode Capital Management ✦ (passive) | 794.01K | +2.4% | $2.68M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 17 | Geode Capital Management ✦ (passive) | 794.01K | +2.4% | $2.68M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 18 | State Street Global Advisors ✦ (passive) | 719.21K | +0.7% | $2.42M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 390.65K | -1.2% | $1.32M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 390.65K | -1.2% | $1.32M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 21 | Renaissance Technologies ✦ | 267.80K | +1.1% | $902,486 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 22 | Two Sigma Investments ✦ | 89.31K | -30.6% | $300,978 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 28.73K | -9.5% | $96,806 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 28.73K | -9.5% | $96,806 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 28.73K | -9.5% | $96,806 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 28.73K | -9.5% | $96,806 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 27 | T. Rowe Price ✦ | 16.31K | +24.8% | $55,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Wellington Management | $546,264 | was 0.0% |
| Millennium Management | $339,634 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 124 holders, 37.97M shares, $395.07M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.